Analyst Robert LeBoyer - NeuroSense (NRSN) - PrimeC NDS; New ALS Data

Read the full equity research on NeuroSense Therapeutics (NRSN) here: https://www.channelchek.com/news-channel/neurosense-therapeutics-ltd-nrsn-new-data-to-be-added-to-canadian-nds-application-for-primec **About NeuroSense Therapeutics:** NeuroSense Therapeutics plans to include additional analyses from its Phase 2b PARADIGM trial of PrimeC in its Canadian New Drug Submission (NDS). The new data include analyses of neurofilament light chain (NfL), a biomarker associated with neuronal damage and death in ALS. PrimeC patients showed greater reductions in NfL levels than placebo patients, consistent with other clinical findings. The additional analyses have moved the anticipated NDS submission from December 2026 to March 2027. Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc. Refer to the full report for the price target, fundamental analysis, and rating. This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D). *Analyst certification and important disclosures included in the full report. NOTE: Investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.*